Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

Note that some links may require registration or subscription. An Air India passenger plane bound for London with more than ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

A Rockville biotech just struck a deal with Canadian asset management firm Sagard that will funnel the local company crucial ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...